BioMarin Pharmaceutical Inc.
GB ˙ LSE ˙ US09061G1013
54,65 $ ↑0,60 (1,11%)
2026-06-03
AKTIENPREIS
SecurityGB:0HNC / BioMarin Pharmaceutical Inc.
InstitutionVan Eck Associates Corp
Latest Disclosed Ownership181,882 shares
Latest Disclosed Value $ 10,275
Van Eck Associates Corp reports 24.55% increase in ownership of 0HNC / BioMarin Pharmaceutical Inc.

On May 15, 2026 - Van Eck Associates Corp filed a 13F-HR form disclosing ownership of 181,882 shares of BioMarin Pharmaceutical Inc. (GB:0HNC) valued at $10,130,827 USD as of March 31, 2026. The entity filed a previous 13F-HR on February 13, 2026 disclosing 146,037 shares of BioMarin Pharmaceutical Inc.. This represents a change in shares of 24.55% during the quarter. The current value of the position is $9,939,851 USD.

Institutional Ownership: 13F and NPORT Filings

The Security and Class in the table below are shown exactly as filed by the investor. We do our best to track continuity of investments through acquisitions, and this will be reflected in the table as changes in names. In addition to descriptive data, performance of the investment is shown over time. To calculate quarterly performance, we first calculate cost basis of the shares purchased during the quarter, then use that to calculate gross profit. Quarterly return is Gross Profit / Starting Portfolio value.

Note that cost basis is calculated and stored in thousands, so small quarterly changes in shares frequently result in a cost basis of zero.

Upgrade to unlock premium data and export to Excel .

Disclosed Equity Positions (from 13F/NPORT Filings)
File
Date		 Effective
Date		Form Security Class ID Avg Price
Paid (Est)		 Reported
Shares		 ΔShares ΔShares
(%)		 Reported
Value
(x1000)		 ΔValue
(%)		 Alloc
(%)		 ΔAlloc ΔAlloc (%) Cost Basis
(x1000)		 Unrealized
Gain/Loss
(x1000)
2026-05-15 2026-03-31 13F BioMarin Pharmaceutical COM 09061G101 181,882 35,845 24.55 10 25.00 0.0067
2026-02-13 2025-12-31 13F BioMarin Pharmaceutical COM 09061G101 146,037 28,207 23.94 9 33.33 0.0072
2025-11-13 2025-09-30 13F BioMarin Pharmaceutical COM 09061G101 117,830 6,932 6.25 6 0.00 0.0059
2025-08-14 2025-06-30 13F BioMarin Pharmaceutical COM 09061G101 110,898 -4,028 -3.50 6 -25.00 0.0069
2025-05-15 2025-03-31 13F BioMarin Pharmaceutical COM 09061G101 114,926 12,607 12.32 8 33.33 0.0105
2025-01-29 2024-12-31 13F BioMarin Pharmaceutical COM 09061G101 102,319 -29,813 -22.56 7 -33.33 0.0086
2024-10-29 2024-09-30 13F BioMarin Pharmaceutical COM 09061G101 132,132 -1,390 -1.04 9 -10.00 0.0115
2024-07-31 2024-06-30 13F BioMarin Pharmaceutical COM 09061G101 133,522 -9,315 -6.52 11 -16.67 0.0156
2024-04-30 2024-03-31 13F BioMarin Pharmaceutical COM 09061G101 142,837 8,741 6.52 12 0.00 0.0189
2024-02-05 2023-12-31 13F BioMarin Pharmaceutical COM 09061G101 134,096 -20,975 -13.53 13 -7.69 0.0235
2023-11-08 2023-09-30 13F BioMarin Pharmaceutical COM 09061G101 155,071 -4,417 -2.77 14 0.00 0.0301
2023-08-03 2023-06-30 13F BioMarin Pharmaceutical COM 09061G101 159,488 -5,349 -3.25 14 -18.75 0.0303
2023-05-03 2023-03-31 13F BioMarin Pharmaceutical COM 09061G101 164,837 -26,611 -13.90 16 -15.79 0.0365
2023-02-08 2022-12-31 13F BioMarin Pharmaceutical COM 09061G101 191,448 53,398 38.68 20 -99.84 0.0512
2022-10-27 2022-09-30 13F BioMarin Pharmaceutical COM 09061G101 138,050 -41,721 -23.21 11,702 -21.45 0.0348
2022-08-03 2022-06-30 13F BioMarin Pharmaceutical COM 09061G101 179,771 23,834 15.28 14,898 23.91 0.0395
2022-05-10 2022-03-31 13F BioMarin Pharmaceutical COM 09061G101 155,937 13,129 9.19 12,023 -4.71 0.0248
2022-01-26 2021-12-31 13F BioMarin Pharmaceutical COM 09061G101 142,808 -6,167 -4.14 12,617 9.58 0.0292
2021-11-03 2021-09-30 13F BioMarin Pharmaceutical COM 09061G101 148,975 -24,399 -14.07 11,514 -20.41 0.0289
2021-08-10 2021-06-30 13F BioMarin Pharmaceutical COM 09061G101 173,374 -8,946 -4.91 14,466 5.08 0.0342
2021-05-13 2021-03-31 13F BioMarin Pharmaceutical COM 09061G101 182,320 -10,693 -5.54 13,767 -18.66 0.0374
2021-02-09 2020-12-31 13F BioMarin Pharmaceutical COM 09061G101 193,013 23,265 13.71 16,925 31.06 0.0493
2020-12-04 2020-09-30 13F/A-1 BioMarin Pharmaceutical COM 09061G101 169,748 -33,697 -16.56 12,914 -48.54 0.0411
2020-11-12 2020-09-30 13F BioMarin Pharmaceutical COM 09061G101 169,748 -33,697 12,914 40,037.9707
2020-08-14 2020-06-30 13F/A-1 BioMarin Pharmaceutical COM 09061G101 203,445 41,280 25.46 25,093 83.12 0.0874
2020-08-10 2020-06-30 13F BioMarin Pharmaceutical COM 09061G101 203,445 41,280 25,093 85,247.2287
2020-05-12 2020-03-31 13F BioMarin Pharmaceutical COM 09061G101 162,165 -19,503 -10.74 13,703 -10.79 0.0696
2020-02-13 2019-12-31 13F BioMarin Pharmaceutical COM 09061G101 181,668 2,474 1.38 15,360 27.17 0.0593
2019-11-08 2019-09-30 13F BioMarin Pharmaceutical COM 09061G101 179,194 -3,534 -1.93 12,078 -22.83 0.0566
2019-08-07 2019-06-30 13F BioMarin Pharmaceutical COM 09061G101 182,728 -17,510 -8.74 15,651 -12.01 0.0754
2019-05-13 2019-03-31 13F BioMarin Pharmaceutical COM 09061G101 200,238 9,313 4.88 17,787 9.41 0.0874
2019-02-12 2018-12-31 13F BioMarin Pharmaceutical COM 09061G101 190,925 -18,430 -8.80 16,257 -19.92 0.0815
2018-11-13 2018-09-30 13F BioMarin Pharmaceutical COM 09061G101 209,355 10,677 5.37 20,301 8.47 0.0990
2018-08-13 2018-06-30 13F BioMarin Pharmaceutical COM 09061G101 198,678 -38,734 -16.32 18,715 -2.76 0.0875
2018-05-11 2018-03-31 13F BioMarin Pharmaceutical COM 09061G101 237,412 -41,194 -14.79 19,247 -22.53 0.0957
2018-02-12 2017-12-31 13F BioMarin Pharmaceutical COM 09061G101 278,606 -83,901 -23.14 24,843 -26.37 0.1225
2017-11-09 2017-09-30 13F BioMarin Pharmaceutical COM 09061G101 362,507 41,145 12.80 33,739 15.60 0.1723
2017-08-11 2017-06-30 13F BioMarin Pharmaceutical COM 09061G101 321,362 -11,421 -3.43 29,186 -0.09 0.1596
2017-05-11 2017-03-31 13F BioMarin Pharmaceutical COM 09061G101 332,783 15,988 5.05 29,212 11.31 0.1288
2017-02-09 2016-12-31 13F BioMarin Pharmaceutical COM 09061G101 316,795 36,542 13.04 26,243 1.21 0.1308
2016-11-14 2016-09-30 13F BioMarin Pharmaceutical COM 09061G101 280,253 -8,131 -2.82 25,929 15.57 0.1207
2016-08-12 2016-06-30 13F BioMarin Pharmaceutical COM 09061G101 288,384 21,418 8.02 22,436 1.89 0.1150
2016-05-13 2016-03-31 13F BioMarin Pharmaceutical COM 09061G101 266,966 -55,851 -17.30 22,019 -34.89 0.1483
2016-02-12 2015-12-31 13F BioMarin Pharmaceutical COM 09061G101 322,817 71,513 28.46 33,818 27.77 0.2683
2015-11-12 2015-09-30 13F BioMarin Pharmaceutical COM 09061G101 251,304 -38,203 -13.20 26,467 -33.16 0.2034
2015-08-12 2015-06-30 13F BioMarin Pharmaceutical COM 09061G101 289,507 -12,097 -4.01 39,599 5.36 0.2342
2015-05-14 2015-03-31 13F BioMarin Pharmaceutical COM 09061G101 301,604 -14,129 -4.47 37,586 31.69 0.2170
2015-02-13 2014-12-31 13F BioMarin Pharmaceutical COM 09061G101 315,733 43,571 16.01 28,542 45.33 0.1774
2014-11-14 2014-09-30 13F BioMarin Pharmaceutical COM 09061G101 272,162 -2,554 -0.93 19,639 14.92 0.1040
2014-08-14 2014-06-30 13F BioMarin Pharmaceutical COM 09061G101 274,716 -73,010 -21.00 17,090 -27.95 0.0789
2014-05-08 2014-03-31 13F BIOMARIN PHARMACEUTICAL COM 09061G101 347,726 133,587 62.38 23,718 57.44 0.1177
2014-02-12 2013-12-31 13F BIOMARIN PHARMACEUTICAL COM 09061G101 214,139 -56,701 -20.94 15,065 -22.93 0.0761
2013-11-14 2013-09-30 13F BIOMARIN PHARMACEUTICAL COM 09061G101 270,840 44,966 19.91 19,547 55.26 0.0995
2013-08-14 2013-06-30 13F BIOMARIN PHARMACEUTICAL COM 09061G101 225,874 225,874 12,590 0.0686
Legend
Shares
The total number of shares held by the institution at the end of the reporting period (the effective date). This is provided in the filing.
Value
The total value of the shares as of the effective date. This is provided in the filing.
Avg. Share Price
The weighted average share price of the shares held by the institution. We use FIFO accounting to determine this price
Class
This is the security class as indicated by the filer. There are a variety of values for this field. Common values include "EC" = equity common, "EP" - equity preferred
Allocation (%)
The percent of the institution's portfolio that this position represents. This is provided in NPORT filings. For 13F filings, we calculate it.
Change in Allocation
The change in allocation from the prior reporting period. This is calculated as current allocation - prior allocation.
Change in Allocation (%)
The percent change in allocation from the prior reporting period. This is calculated as (current allocation - prior allocation) / prior allocation.
Cost Basis
The total cost of the shares held. This is calculated as reported shares * avg. share price
Unrealized Gain/Loss
This is the market value of the position as of the effective date minus the cost basis.